Regeneron Pharmaceuticals Inc. has announced its successful bid to acquire the majority of assets from 23andMe Holding Co. for $256 million. This acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank, aiming to maintain consumer genomics services without interruption. The transaction, pending bankruptcy court and regulatory approvals, is expected to finalize in the third quarter of 2025. Regeneron plans to operate 23andMe as a subsidiary, excluding its Lemonaid Health business, and emphasizes its commitment to customer data privacy and ethical use.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9454038-en) on May 19, 2025, and is solely responsible for the information contained therein.